中国生物制药：LM-350「CDH17 ADC」获美国FDA IND批件

Core Viewpoint - The company has received FDA approval for clinical trials of its self-developed anti-tumor drug LM-350 "CDH17ADC," which targets the mechanism of CDH17 in tumors, aiming to provide more effective treatment options for patients [1] Group 1 - The drug LM-350 "CDH17ADC" is designed to address the role of CDH17 in tumors [1] - The FDA's IND approval marks a significant milestone for the company's research and development efforts [1] - The new drug aims to enhance treatment efficacy for patients suffering from cancer [1]